Bulletin
Investor Alert

UroGen Pharma Ltd.

NAS: URGN

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jul 10, 2020, 4:00 p.m.

/zigman2/quotes/202929873/composite

$

23.35

Change

0.00 0.00%

Volume

Volume 1,863

Quotes are delayed by 20 min

/zigman2/quotes/202929873/composite

Previous close

$ 23.65

$ 23.35

Change

-0.30 -1.27%

Day low

Day high

$23.10

$24.02

Open

52 week low

52 week high

$13.12

$37.08

Open

Company Description

UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology. Its pipeline includes upper tract urothelial carcinoma, low grade non muscle inv...

UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology. Its pipeline includes upper tract urothelial carcinoma, low grade non muscle invasive bladder cancer, carcinoma in situ of the bladder, and overactive bladder. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Valuation

Price to Sales Ratio

38,058.00

Price to Book Ratio

3.89

Enterprise Value to Sales

30,002.60

Total Debt to Enterprise Value

0.00

Efficiency

Revenue/Employee

104.00

Income Per Employee

-607,780.00

Total Asset Turnover

0.00

Liquidity

Current Ratio

7.63

Quick Ratio

7.63

Cash Ratio

7.58

Profitability

Operating Margin

-608,211.11

Pretax Margin

-584,144.44

Net Margin

-584,144.44

Return on Assets

-68.73

Return on Equity

-77.77

Return on Total Capital

-80.20

Return on Invested Capital

-77.03

Capital Structure

Total Debt to Total Equity

1.44

Total Debt to Total Capital

1.42

Total Debt to Total Assets

1.29

Long-Term Debt to Equity

1.44

Long-Term Debt to Total Capital

1.42

Officers and Executives

Name Age Officer Since Title
Ms. Elizabeth Barrett 56 2019 President, Chief Executive Officer & Director
Mr. Peter P. Pfreundschuh 49 2018 Chief Financial Officer
Dr. Moran Mieron 48 - Director-Research & Pre-Clinical Affairs
Dr. Mark P. Schoenberg 61 2016 Medical Director
Dr. Marina Konorty - 2011 Senior Vice President-Research & Development

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
06/04/2020 Mark P. Schoenberg
Chief Medical Officer
349   Disposition at $27.51 per share. 9,600
06/04/2020 Mark P. Schoenberg
Chief Medical Officer
1,042   Derivative/Non-derivative trans. at $0 per share. 0
05/20/2020 Peter P. Pfreundschuh
Chief Financial Officer
358   Disposition at $25.07 per share. 8,975
05/20/2020 Peter P. Pfreundschuh
Chief Financial Officer
1,041   Derivative/Non-derivative trans. at $0 per share. 0
05/12/2020 Elizabeth Barrett
Chief Executive Officer
35,229   Derivative/Non-derivative trans. at $0 per share. 0
04/27/2020 Mark P. Schoenberg
Chief Medical Officer
70   Disposition at $24.35 per share. 1,704
04/27/2020 Stephen Mullennix
Chief Operating Officer
145   Disposition at $24.35 per share. 3,530
04/27/2020 Peter P. Pfreundschuh
Chief Financial Officer
141   Disposition at $24.35 per share. 3,433
04/26/2020 Mark P. Schoenberg
Chief Medical Officer
208   Derivative/Non-derivative trans. at $0 per share. 0
04/26/2020 Stephen Mullennix
Chief Operating Officer
417   Derivative/Non-derivative trans. at $0 per share. 0
04/26/2020 Peter P. Pfreundschuh
Chief Financial Officer
417   Derivative/Non-derivative trans. at $0 per share. 0
03/04/2020 Mark P. Schoenberg
Chief Medical Officer
345   Derivative/Non-derivative trans. at $29.5 per share. 10,177
03/04/2020 Mark P. Schoenberg
Chief Medical Officer
1,042   Derivative/Non-derivative trans. at $0 per share. 0
02/20/2020 Peter P. Pfreundschuh
Chief Financial Officer
360   Disposition at $29.68 per share. 10,684
02/20/2020 Peter P. Pfreundschuh
Chief Financial Officer
1,042   Derivative/Non-derivative trans. at $0 per share. 0
02/14/2020 Stephen Mullennix
Chief Operating Officer
612   Disposition at $28.04 per share. 17,160
02/14/2020 Stephen Mullennix
Chief Operating Officer
1,759   Derivative/Non-derivative trans. at $0 per share. 0
01/27/2020 Mark P. Schoenberg
Chief Medical Officer
322   Disposition at $29.15 per share. 9,386
01/27/2020 Stephen Mullennix
Chief Operating Officer
684   Disposition at $29.26 per share. 20,013
01/27/2020 Peter P. Pfreundschuh
Chief Financial Officer
667   Disposition at $29.28 per share. 19,529
01/26/2020 Mark P. Schoenberg
Chief Medical Officer
833   Derivative/Non-derivative trans. at $0 per share. 0
01/26/2020 Stephen Mullennix
Chief Operating Officer
1,666   Derivative/Non-derivative trans. at $0 per share. 0
01/26/2020 Peter P. Pfreundschuh
Chief Financial Officer
1,666   Derivative/Non-derivative trans. at $0 per share. 0
/news/latest/company/us/urgn

MarketWatch News on URGN

  1. UroGen Pharma stock price target cut to $41 from $61 at Stifel Nicolaus

    8:07 a.m. Oct. 21, 2019

    - Tomi Kilgore

  2. UroGen Pharma stock price target cut to $61 from $63 at Stifel Nicolaus

    9:12 a.m. Aug. 13, 2019

    - Tomi Kilgore

  3. UroGen initiated at neutral at JPMorgan

    8:22 a.m. May 30, 2019

    - Ciara Linnane

  4. UroGen Pharma upgraded to outperform from market perform at Raymond James

    7:58 a.m. April 4, 2018

    - Tomi Kilgore

/news/nonmarketwatch/company/us/urgn

Other News on URGN

  1. 10-Q: UROGEN PHARMA LTD.

    7:07 a.m. May 7, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  2. UroGen Is A Compelling Value With Recent FDA Approval

    2:50 a.m. April 28, 2020

    - Seeking Alpha

  3. 7 Stocks to Buy for Their Double-Digit Growth Prospects

    11:05 a.m. April 27, 2020

    - InvestorPlace.com

  4. INO, BBBY among premarket gainers

    9:19 a.m. April 16, 2020

    - Seeking Alpha

  5. FDA OKs UroGen's mitomycin gel for rare urothelial cancer

    3:21 p.m. April 15, 2020

    - Seeking Alpha

  6. UroGen (URGN) Looks Good: Stock Adds 8.1% in Session

    8:53 a.m. April 6, 2020

    - Zacks.com

  7. UroGen's UGN-102 shows positive effect ih bladder cancer study

    8:34 a.m. April 3, 2020

    - Seeking Alpha

  8. Stocks To Watch: 0% To The Rescue?

    8:49 a.m. March 14, 2020

    - Seeking Alpha

  9. 10-K: UROGEN PHARMA LTD.

    8:52 a.m. March 2, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  10. UBS upgrades Madrigal Pharma in premarket analyst action

    9:10 a.m. Jan. 9, 2020

    - Seeking Alpha

  11. Weekly CEO Buys Highlight

    3:06 p.m. Dec. 1, 2019

    - GuruFocus.com

  12. 10-Q: UROGEN PHARMA LTD.

    8:34 a.m. Nov. 12, 2019

    - Edgar Online - (EDG = 10Q, 10K)

  13. Agenus up 8% on zalifrelimab license deal

    12:45 p.m. Nov. 11, 2019

    - Seeking Alpha

  14. Loading more headlines...

At a Glance

UroGen Pharma Ltd.

400 Alexander Park Drive

4th floor

Princeton, New Jersey 08540

Phone

1 6467689780

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

$18,000

Net Income

$-105.15M

Employees

173.00

/news/pressrelease/company/us/urgn

Press Releases on URGN

  1. UroGen Pharma to Present at Jefferies Virtual Healthcare Conference

    8:00 a.m. June 1, 2020

    - BusinessWire - BZX

  2. Tuesday's ETF with Unusual Volume: EIS

    12:07 p.m. April 21, 2020

    - MarketNewsVideo.com

  3. Loading more headlines...
Link to MarketWatch's Slice.